BALTIMORE — Global pharma major Lupin Limited (Lupin) has announced the launch of ipratropium bromide nasal solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium bromide nasal solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals.
Ipratropium bromide nasal solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium bromide nasal solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older.
Ipratropium bromide nasal solution (RLD Atrovent) had estimated annual sales of USD 63 million in the U.S. (IQVIA MAT May 2025).
